DS
SVNT

David Shaw’s SAVIENT PHARMACEUTICALS INC SVNT Stock Holding History

David Shaw’s Portfolio SVNT Stock Details SVNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-190,359
Closed -$107K – 4618
2013
Q2 		$107K Buy
+190,359
New +$133K ﹤0.01% 3867

Other funds holding SVNT

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

David Shaw's SVNT Position: Q3 2013 in Review

David Shaw sold out of SAVIENT PHARMACEUTICALS INC (SVNT) in Q3 2013, closing a stake of 190,359 shares — an estimated $107K sold.

David Shaw first reported a position in SVNT in Q2 2013 and held it in 1 quarter. The position peaked at $107K in Q2 2013. 41 funds tracked by Wall St. Rank hold SVNT as of Q3 2013.

  • David Shaw reported no remaining SAVIENT PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • David Shaw sold 190,359 SAVIENT PHARMACEUTICALS INC shares in Q3 2013, an estimated $107K.
  • David Shaw first reported a position in SAVIENT PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • David Shaw's SAVIENT PHARMACEUTICALS INC position peaked at $107K in Q2 2013.
  • 41 funds tracked by Wall St. Rank held SAVIENT PHARMACEUTICALS INC as of Q3 2013.

Based on D.E. Shaw & Co's 13F filing for Q3 2013, filed 14 Nov 2013.